The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The company had achieved the highest "A" rating in Climate Change
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Subscribe To Our Newsletter & Stay Updated
